Dosing questions encompass Novo Nordisk next-gen weight reduction drug
CHICAGO — Novo Nordisk’s next-generation weight problems injection concentrating on the amylin hormone confirmed substantial weight reduction in an early examine, however comparable efficacy throughout completely different doses and excessive charges of unintended effects elevate questions on which dose Novo will pursue going ahead.
Within the Part 1/2 examine testing the drug, known as amycretin, sufferers on the best dose of 60 mg misplaced on common 24.3% of their weight at 36 weeks, whereas these on placebo misplaced 1.1%, in line with outcomes printed Friday within the Lancet that may even be introduced on the American Diabetes Affiliation convention. These outcomes counsel amycretin may very well be more practical than different medicine available on the market.
In one other a part of the examine testing 20-mg, 5-mg, and 1.25-mg doses of amycretin, sufferers additionally skilled substantial weight reduction, however with overlapping weight-loss curves. The discovering is uncommon since researchers usually count on a dose-dependent impact, the place sufferers on larger doses lose extra weight sooner.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
